基于铁死亡的抗肝癌药物的研究进展  

Research Progress of Anti-hepatocellular Carcinoma Drugs Based on Ferroptosis

作　　者：袁成 刘瑞文[1] 孙俊[1] 徐新明[1] 陈健[1] YUAN Cheng;LIU Ruiwen;SUN Jun;XU Xinming;CHEN Jian(Department of Hepatobiliary Surgery,Kunshan Hospital Affiliated to Jiangsu University,Suzhou 215300,China;School of Medicine,Jiangsu University,Zhenjiang 212013,China)

机构地区：[1]江苏大学附属昆山医院肝胆外科,江苏苏州215300 [2]江苏大学医学院,江苏镇江212013

出　　处：《医学综述》2023年第24期5812-5818,共7页Medical Recapitulate

基　　金：苏州市医学重点学科项目(Szxk201820)。

摘　　要：肝癌是最常见的恶性肿瘤之一,其早期症状较为隐匿,大部分患者一经确诊即为晚期,失去手术机会,多选择药物治疗。然而,现有治疗肝癌的药物并不能明显延长肝癌患者的总生存期,急需新型的药物改善肝癌预后。铁死亡是新发现的一种细胞程序性死亡方式,其可通过影响脂质代谢、铁代谢等相关途径诱导肝癌细胞死亡,从而抑制肝癌的进展。同时,大量新型的铁死亡诱导药物在基础实验中显示出了可观的抗肝癌效果。因此,铁死亡诱导药物有望成为新型抗肝癌药物,但还需要进一步的动物实验及临床研究证明其可行性。Hepatocellular carcinoma is one of the most common malignant tumors.Its early symptoms are relatively hidden,and most patients are already at an advanced stage once diagnosed,losing the opportunity for surgery,making drug therapy the choice.However,the existing drugs for the treatment of hepatocellular carcinoma cannot significantly improve the overall survival time of teh patients,thus,there is an urgent need for new drugs to improve the prognosis.Ferroptosis is a newly discovered way of programmed cell death,which can induce the death of hepatocellular carcinoma cells by affecting lipid metabolism,iron metabolism and other related pathways,thereby inhibiting the progression of hepatocellular carcinoma.At the same time,a large number of different ferroptosis-inducing drugs have shown considerable anti-hepatocellular carcinoma effects in basic experiments.Therefore,ferroptosis-inducing drugs are expected to become new anti-hepatocellular carcinoma drugs,but further animal experiments and clinical studies are needed to prove the feasibility.

关 键 词：肝癌 铁死亡 药物 

分 类 号：R735.7[医药卫生—肿瘤]